Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q3 FY25 results · Oct–Dec 2024
Torrent Pharmaceuticals reported revenue from operations of ₹2,809.00 crore (up 2.8% from Q3 FY24) and net profit of ₹503.00 crore (up 13.5% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,809.00 | 2,732.00 | +2.8% | 2,889.00 | −2.8% |
| Other income | 33.00 | (33.00) | Turned profit | (16.00) | Turned profit |
| Total income | 2,842.00 | 2,699.00 | +5.3% | 2,873.00 | −1.1% |
| Profit before tax | 691.00 | 631.00 | +9.5% | 661.00 | +4.5% |
| Net profit for the period | 503.00 | 443.00 | +13.5% | 453.00 | +11.0% |
| EPS, basic (₹) | 14.88 | 13.10 | +13.6% | 13.37 | +11.3% |
| Net margin (%) | 17.9 | 16.2 | 15.7 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,377.00 | 2,123.00 | +12.0% | 2,434.00 | −2.3% |
| Other income | 3.00 | (11.00) | Turned profit | (7.00) | Turned profit |
| Total income | 2,380.00 | 2,112.00 | +12.7% | 2,427.00 | −1.9% |
| Profit before tax | 651.00 | 430.00 | +51.4% | 670.00 | −2.8% |
| Net profit for the period | 485.00 | 297.00 | +63.3% | 460.00 | +5.4% |
| EPS, basic (₹) | 14.33 | 8.78 | +63.2% | 13.60 | +5.4% |
| Net margin (%) | 20.4 | 14.0 | 18.9 |
Consolidated
- Filed with BSE
- 24 Jan 2025, 17:29 IST
- Board meeting
- 24 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jan 2025, 17:29 IST
- Board meeting
- 24 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Audited
- Source
- XBRL filing on BSE